NTLA Intellia Therapeutics, Inc.

$11.74▼ -1.59% Healthcare Other
After hours $11.78▲ +0.34% Sep 11, 7:46 PM ET
Volume 2.70M Avg Volume (10D) 3.33M
Key Metrics & Fundamentals
Market Cap
$1.65B
P/E Ratio
–
Div Yield
–%
52W Range
7.95 - 28.25
% vs 50 MA
-6.41%
% vs 200 MA
-7.04%
RSI-14
40.9
MACD Histogram
-0.1000
Beta (1Y vs SPY)
2.37
Free Cash Flow
-$84.92M
Gross Rev
$7.66M
Gross Profit
$7.66M
EBITDA
-$111.01M
COGS
–
Operating Exp
$120.42M
Operating Income
-$112.76M
EBIT
-$112.76M
Pretax Income
-$106.63M
Net Income
-$106.63M
EPS (Diluted)
-0.80
Price & Volume History
Loading chart…
Recent News
Intellia Therapeutics (NTLA) Secured a Facility for Up to $400M. Is It Worth the Cost?
Insider Monkey · Sep 10, 2026 6:42 PM
FDA Accepts & Gives Priority Review to Intellia's BLA for HAE Drug
Zacks · Sep 9, 2026 2:05 PM
3 Promising Genomics Stocks in the Spotlight in 2026
Zacks · Sep 8, 2026 4:46 PM
Wedbush Adjusts Intellia Therapeutics Price Target to $13 From $12, Maintains Neutral Rating
MT Newswires · Sep 8, 2026 3:18 PM
Cathie Wood’s Biotech Bet Intellia Secured An FDA Priority Review For Rare Genetic Disorder Therapy – Retail Sees Upside In NTLA’s Platform
Stocktwits · Sep 8, 2026 2:08 PM
Intellia Therapeutics Says FDA Accepts Lonvo-z BLA for Hereditary Angioedema
MT Newswires · Sep 8, 2026 1:59 PM
Intellia Therapeutics Shares Rise as FDA Grants Priority Review to Lonvo-z
InvestorsHub · Sep 8, 2026 12:48 PM
Intellia Therapeutics Announces FDA Acceptance of Biologics License Application with Priority Review for Lonvoguran Ziclumeran (Lonvo-z) for Hereditary Angioedema (HAE)
GlobeNewswire · Sep 8, 2026 12:00 PM
Intellia Therapeutics (NTLA) Secures $400 Million As Investors Ask If The Upside Is Priced In
Simply Wall St. · Sep 5, 2026 4:13 PM
Should Intellia’s Milestone-Linked OrbiMed Loan Reshape Funding Risk Perceptions For Intellia Therapeutics (NTLA) Investors?
Simply Wall St. · Sep 5, 2026 9:08 AM
Financial Overview - Income Statement Quarterly

See NTLA's money flow as a full page

Social Sentiment
Avg +0.66 · 28 posts
NewsDiscussionWhat if the next AI is genetics?
r/StockMarket · Jun 2, 2026
The post highlights NTLA's role in gene-editing therapies, indicating a positive view.
positive +0.60
NewsDiscussionWhat if the next AI is genetics?
r/stocks · Jun 2, 2026
Highlights NTLA's focus on gene editing, aligning with the post's theme.
positive +0.70
DiscussionDDTradeBack to picks?
r/wallstreetbets · May 9, 2026
NTLA is described as an 'asymmetric play' with a 'short term acquisition narrative', indicating a positive outlook.
positive +0.70
NewsDD$NTLA short squeze, viable or not
r/wallstreetbets · Jan 27, 2026
The post expresses optimism due to the short squeeze and FDA approval, suggesting a potential upward trend for the stock.
positive +0.60
DDNewsDiscussionIntellia, NTLA, highest shorted stock on Wall Street with breakthrough gene editing technology
r/wallstreetbets · Jan 13, 2026
The post expresses optimism about the stock's future following the FDA hold lift and trial resumption.
positive +0.70
Page 1 of 6 (28 total)
AI Analysis

Click Generate Analysis for an AI-powered summary, bull & bear case, and recent performance review.

Not financial advice. All data, scores, charts, and analysis on this site are provided for informational and educational purposes only and do not constitute financial, investment, legal, or tax advice. Past performance is not indicative of future results. See our Legal Notice for full details.
An unhandled error has occurred. Reload 🗙